Freeline to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced participation in key virtual investor conferences. CEO Michael Parini will engage in Fireside Chats at the H.C. Wainwright Gene Therapy Conference on March 30, 2022, and at the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. Live streams and on-demand presentations will be available on the Company’s website. Freeline focuses on developing AAV vector-mediated gene therapies for diseases like hemophilia B and Fabry disease, aiming to provide one-time treatments for debilitating inherited conditions.

LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that senior management will participate in the following virtual investor conferences:

• H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022, where Chief Executive Officer Michael Parini will participate in a Fireside Chat. An on-demand presentation will be made available on March 30, 2022, at 7:00 am EDT in the Investors section of the Company’s website.
  
  
• 21^st Annual Needham Virtual Healthcare Conference on April 11 – 14, 2022, where Chief Executive Officer Michael Parini will participate in a Fireside Chat. The live stream will be available on Wednesday, April 13, 2022, at 8:45 am EDT. A replay will be available in the Investors section on the Company’s website on Wednesday, April 13, 2022, at 9:45 am EDT.
  

Senior management will also participate in virtual one-on-one meetings with investors at both conferences as well as at the Guggenheim 3^rd Annual Genomic Medicine and Rare Disease Day from March 31 – April 1, 2022.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.

IR Contact:
investor@freeline.life

Media Contact:
Arne Naeveke, PhD
Vice President, Head of Corporate Communications
arne.naeveke@freeline.life
+1 617 312 2521

FAQ

What events will Freeline Therapeutics (FRLN) participate in March 2022?

Freeline Therapeutics will participate in the H.C. Wainwright Gene Therapy Conference on March 30, 2022, and the Guggenheim 3rd Annual Genomic Medicine and Rare Disease Day from March 31 to April 1, 2022.

When is the Needham Virtual Healthcare Conference for Freeline (FRLN)?

The 21st Annual Needham Virtual Healthcare Conference will occur from April 11-14, 2022, with a Fireside Chat by CEO Michael Parini on April 13, 2022.

How can I access Freeline's presentations during the investor conferences?

Presentations can be accessed via the Investors section of Freeline's website, with on-demand and live stream options available during the conferences.

What is Freeline Therapeutics focused on developing?

Freeline Therapeutics is focused on developing adeno-associated virus (AAV) vector-mediated gene therapies for conditions like hemophilia B and Fabry disease.